Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic (OTCMKTS:BVNRY) was the target of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 3,783 shares, a decrease of 60.7% from the April 15th total of 9,626 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 5,552 shares, the days-to-cover ratio is presently 0.7 days.

Bavarian Nordic Trading Down 1.3%

OTCMKTS BVNRY opened at $9.69 on Friday. The firm has a market capitalization of $2.30 billion, a P/E ratio of 12.75 and a beta of 1.21. The business has a fifty day simple moving average of $9.85 and a 200 day simple moving average of $10.06. Bavarian Nordic has a 12 month low of $8.11 and a 12 month high of $13.00.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. The business had revenue of $165.70 million during the quarter. Bavarian Nordic had a return on equity of 9.37% and a net margin of 19.74%.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.